On September 4, 2025, Lila Biologics, an artificial intelligence (AI)/machine learning (ML)-driven protein therapeutics biotech company, announced a global licensing and multi-target research collaboration with Eli Lilly and Company focused on the discovery, development, and commercialization of novel radioligand therapies (RLTs) for imaging and treatment of solid tumors. Wilson Sonsini Goodrich & Rosati serves as IP counsel to Lila and advised the company on IP matters related to the transaction.

Lila—which spun out of Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design—also announced the launch of its two protein therapeutic platforms to combat cancer and non-oncology diseases. Lila’s targeted radiotherapy (TRT)/oncology platform for solid tumors and long-acting injectables (LAI) platform for non-oncology conditions are utilizing Lila’s proprietary AI/ML-powered protein design engine to create the foundation for new drug discovery and breakthrough treatments for patients. Lila’s TRT platform will be utilized in its collaboration with Lilly to generate novel tumor-targeting radiopharmaceuticals. As part of the collaboration, Lila will design precision-targeted proteins for radioligand therapy and plans to undertake program discovery through development candidate selection. Lilly will focus on IND-enabling studies, global clinical development, and commercialization. Lila will retain full asset rights to its current proprietary RLT and LAI pipelines, separate from the tumor-targeted radiotherapies they collaborate with Lilly on.

The Wilson Sonsini team that advised Lila on IP matters related to the transaction includes Michael Hostetler, Rachna Ujwal, Irene Kasumba, and Eman Riaz Ahmed.  

For more information, please see Lila’s news release. Additional coverage is available on GeekWire and Inside Precision Medicine.